Ann: Dr Daniel Tillett appointed CEO of Race Oncology, page-65

Can we explicitly mention the 3.1 million options at $4.25?

I love it, he harmlessly misses out on half his base salary in return for options that I consider will be worth at least $100 million dollars before he's finished (and I'm pretty sure @Hunterr agrees with me).



Also Hunterr, you asked for my sum of the parts valuation. Here it is, back of the envelope:
1. AML $1Bn as a clean up or upstream treatment;
2. CPACS 22 million doses of Doxorubicin (ignore all of the other cardio toxic drugs in the world) x $5k per dose (as per Triangle report) = $100Bn annual revenue; say FIC gets 40% mkt share; $40Bn revenue per year; 4 x peak revenue gives $160 Bn;
3. FTO Board in 2021 AGM estimates annual market at $100Bn; same logic as above; valuation based on peak revenue gives $160 Bn.

Ignore AML; total valuation equals $320 Bn (USD); 160 million SoI gives $2,000 USD per share; converts to $3,000 AUD per share; 22.5% dilution (EWexplorer) gives $2,325 per share.

Give the world a break because $320Bn is a lot of money; discount it by 98% gives $46.50 per share